Immunophenotyping in Patients With Osteoporosis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Bonn

About this trial

In addition to a medical history and clinical examination, the diagnosis of osteoporosis includes the measurement of bone surface density by means of dual X-ray absorptiometry (DXA). In addition, blood tests are performed for certain parameters, such as vitamin D, calcium, phosphate and C-reactive protein. In order to optimize osteoporosis diagnostics, the development of further specific methods is required. The modulation of the immune system seems promising in this respect, since osteoporosis is based on an inflammatory reaction. Various regulatory markers of the innate and acquired immune system, which seem to be relevant in the development of the disease, have already been detected in osteoporosis patients. This study may help to gain new insights into disease-associated immunoregulatory markers that could revolutionize both the diagnosis and therapy of osteoporosis in the long term. By means of a simple blood test, patients could be diagnosed early and without additional radiation exposure, and effective therapy options could be developed.

Eligibility criteria

Qualifiers

Adult patients (≥ 18 years) diagnosed with osteoporosis.

Written informed consent from the patient

Disqualifiers

Patients without diagnosed osteoporosis

Patients without written informed consent

Patients < 18 years old

Patients with secondary osteoporosis

Trial design

Treatments tested in this trial

  • Immunological markers

Treatment groups

No treatment groups listed

Sponsors and collaborators